Efficacy and Safety of Intravenous Ferric Carboxymaltose for Postoperative Anemia Management

calendar
23 Sep, 24

Summary: This randomized controlled trial evaluated the effectiveness of postoperative intravenous iron (ferric carboxymaltose) in patients with functional iron deficiency anemia. It found significant improvements in hemoglobin, serum iron, and ferritin levels, with fewer patients requiring blood transfusions.

Introduction

While preoperative anemia has been extensively studied, there is little research on intravenous iron administration for postoperative iron deficiency anemia, with only a few studies showing positive outcomes like improved hemoglobin levels and reduced blood transfusion needs.

Aim

To determine the effect of postoperative intravenous iron (ferric carboxymaltose) administration on iron stores, hemoglobin levels, and long-term outcomes following surgery.

Patient Profile

  • N=201
  • Consecutive routine elective surgical patients who were having major orthopaedic surgery, abdominal, and genitourinary surgery, and other surgeries were recruited
  • Patients ≥18 years who underwent elective surgery with functional iron deficiency anaemia (haemoglobin 70–120 g/L and ferritin ≤100 μg/L or iron saturation ≤20%) measured at day 1 postoperatively

Methods

  • Prospective, open-label, randomised, controlled study of patients

    Fig1: Randomization Chart

         Treatment:

  • Intervention group: Patients received a weight-based calculated average dose of 1000 mg of ferric carboxymaltose. It was administered as 15 mg/kg with a maximum dose of 1000 mg infused over 15 min
  • Control group: Received routine postoperative care consisting of observation with monitoring and blood transfusion when required (as per treating physician’s discretion)

Study endpoints

  • Primary endpoint: Changes in haemoglobin concentrations, iron stores, ferritin concentrations at 4 and 12 weeks postoperatively, and the number of transfused units of blood required postoperatively until discharge.
  • Secondary endpoints: Safety and tolerability of ferric carboxymaltose, length of hospital stay, occurrence of infections and complications during admission in both groups, and the effect on quality of life measured at 4 weeks and 12 weeks postoperatively

Results

Haemoglobin Levels

  • At 4 weeks: Haemoglobin recovery was significantly greater in the intervention group compared to control group (mean difference 7.84 g/L; p<0·0001)
  • At 12 weeks: No significant between-group differences were noted for haemoglobin concentrations

    Serum Iron, Iron Saturation and Serum Ferritin

  • At 4 weeks: Significant improvements in serum iron (5.36 μmol/L, p<0.0001), iron saturation (11.40%; p<0.0001), and serum ferritin concentrations (468 μg/L; p<0.0001) were noted in intervention group compared with control group. No differences were noted in transferrin concentrations (0.06 g/L; p=0.62)
  • At 12 weeks: Ferritin, improvements in serum iron and iron saturation remained higher in the intervention group

Table 1: Haemoglobin and Iron Status Measures in Study Groups

 

Outcomes

Time-point

Intravenous ferric

carboxymaltose

Mean (SD)

Standard care

Mean (SD)

Treatment Effect

 

p-value

Haemoglobin (g/L)

Preoperative

134.50 (11.10)

134.40 (13.10)

–0.61 (–4.31 to 3.09)

0.094

Postoperative (day 1)

106.5 (11.90)

105.5 (13.8)

0.0

 

4 weeks

130.10 (11.30)

121.50 (14.50)

7.84 (3.79 to 11.9)

<0.0001

12 weeks

137.50 (11.10)

133.60 (11.3)

3.07 (–0.99 to 7.14)

>0.24

Serum iron (μmol/L)

Preoperative

14.60 (2.80)

14.50 (3.80)

0.16 (–1.44 to 1.76)

0.77

Postoperative (day 1)

6.00 (3.80)

6.00 (4.50)

0.0

 

4 weeks

16.70 (5.70)

11.40 (5.10)

5.36 (3.62 to 7.09)

<0·0001

12 weeks

17·20 (4·70)

14·90 (6·10)

2·24 (0·28 to 4·21)

0·063

Transferrin (g/L)

Preoperative

2.90 (0.60)

3.11 (0.91)

–0.39 (–1.28 to 0.51)

0.99

Postoperative (day 1)

1.82 (0.43)

2.00 (1.07)

0.0

 

4 weeks

2.44 (4.17)

2.21 (0.46)

0.06 (–0.97 to 1.09)

0.62

12 weeks

3.35 (6.55)

3.98 (7.68)

–0.81 (–2.57 to 0.94)

0.48

Iron saturation (%)

Preoperative

22.30 (4.70)

22.60 (6.70)

0.01 (–2.82 to 2.83)

0.82

Postoperative (day 1)

11.70 (6.60)

12.00 (5.60)

0.0

 

4 weeks

30.90 (11.70)

19.70 (10.70)

11.40 (8.33 to 14.50)

<0.0001

12 weeks

31.70 (9.50)

25.30 (13.10)

6.62 (2.78 to 10.50)

0.0026

Serum ferritin (μg/L)

Preoperative

118.00 (185.00)

188.00 (103.00)

–45.20 (–148.00 to 57.50)

0.18

Postoperative (day 1)

304.00 (423.00)

329.00 (335.00)

0.0

 

4 weeks

717.00 (410.00)

274.00 (296.00)

468.00 (355.00 to 582.00)

<0.0001

12 weeks

481.00 (611.00)

196.00 (231.00)

309.00 (159.00 to 460.00)

0.0026

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Secondary Outcomes

Blood Transfusion

Fewer transfused blood units were given in the intervention group (<1%) than in the control group (5%; incidence rate ratio 0.10; p=0.035)

Hospital Stay

Mean length of hospital stay in the intervention group was 7.8 days vs. 11.6 days in the control group (mean difference –3.8 days; p=0.049)

Quality of Life

There was an apparent difference in the role physical scale in the intravenous iron group at weeks 4 (score difference14.0; p=0·047) and 12 (score difference17.60; p=0·009)

Safety

No adverse events were observed with ferric carboxymaltose treatment

Conclusion

  • Postoperative intravenous ferric carboxymaltose was a safe and effective management strategy for surgical patients with functional iron deficiency anemia
  • It was suggested that patient blood management guidelines be revised to include the use of postoperative intravenous iron infusion to enhance patient outcomes

Reference

Lancet Haematol 2016;3: e415–25